Lates News

Boehringer Ingelheim announced today the final analysis results of the RATIONALE-315 study and long-term follow-up data from the RATIONALE-303 study, showing that Baizean (Tislelizumab) achieved clinically significant overall survival (OS) benefits in both studies. Specific data will be presented at the 2025 World Conference on Lung Cancer (WCLC) in the form of brief oral reports and poster presentations.